

PRESCRIBING INFORMATION

**0.9% SODIUM CHLORIDE INJECTION, USP**

**0.9% (9 mg/mL)**

**Solution**

**Isotonic Vehicle and Electrolyte Replenisher  
intramuscular, intravenous, subcutaneous**

Juno Pharmaceuticals Corp.  
402-2233 Argentia Road  
Mississauga, ON L5N 2X7

Date of preparation:  
June 14, 2023

Submission Control No: 275159

## PRESCRIBING INFORMATION

### 0.9% Sodium Chloride Injection, USP 0.9% (9 mg/mL)

#### Summary Product Information

0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic solution for use as an isotonic vehicle, and liquid and electrolyte replenishment in single dose containers for intravenous, intramuscular, and subcutaneous administration.

The composition, osmolarity, pH range and ionic concentration is provided in Table 1.

**Table 1:** Composition, osmolarity and pH of 0.9% Sodium Chloride Injection, USP in USP Type 1 glass vials.

Product	Volume (mL)	DIN	Composition & Concentration	Ionic Concentration (mmol/L)		Total osmolarity (mOsmol/mL)	pH
			Sodium Chloride (mg/mL)	Na <sup>+</sup>	Cl <sup>-</sup>		
0.9% Sodium Chloride Injection, USP	10 30 50		9	154	154	0.308	4.5-7.0

The container is a single use clear USP Type 1 glass vial. The latex-free rubber stoppers are made of grey chlorobutyl rubber sealed with an aluminum cap.

#### Actions

0.9% Sodium Chloride Injection, USP is a source of electrolytes and water for hydration. It is capable of inducing diuresis depending on the clinical condition of the patient.

Solutions which are di-electrolytic is good in replacing or sustaining electrolytes. For ionic concentration, see Table 1.

#### Indications

0.9% Sodium Chloride Injection, USP is indicated as a source of water and electrolytes.

0.9% Sodium Chloride Injection, USP can be used as a vehicle or diluent for compatible products for parenteral administration.

0.9% Sodium Chloride Injection, USP is also indicated for use as a priming solution in hemodialysis procedures.

## **Contraindications**

0.9% Sodium Chloride Injection, USP is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. 0.9% Sodium Chloride Injection, USP is contraindicated in situations where administration of sodium or chloride could be clinically detrimental. For a complete listing, see the **Dosage Form, Composition and Packaging** section of the Prescribing Information.

## **Warnings and Precautions**

### **General**

0.9% Sodium Chloride Injection, USP should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.

In patients with diminished renal function, administration of 0.9% Sodium Chloride Injection, USP may result in sodium retention.

Intravenous administration of 0.9% Sodium Chloride Injection, USP may cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, clinically relevant electrolyte disturbances, acid-base imbalance and/or central and peripheral edema. The risk of fluid and/or solute overload is directly proportional to the volume of the product intravenously administered.

Excessive administration of potassium free solutions may result in significant hypokalemia.

### **Carcinogenesis and Mutagenesis**

Studies with 0.9% Sodium Chloride Injection, USP have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.

### **Hypersensitivity reactions**

The hypersensitivity/infusion reactions reported with 0.9% Sodium Chloride Injection, USP include hypotension, pyrexia, tremor, chills, urticaria, rash and pruritus.

Stop the infusion immediately if signs or symptoms of hypersensitivity/infusion reactions develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.

### **Risk of Fluid and/or Solute Overload and Electrolyte Disturbances**

Depending on the volume and rate of infusion, intravenous administration of 0.9% Sodium Chloride Injection, USP can cause:

- fluid and/or solute overload resulting in overhydration/hypervolemia and, for example, congested states, including central and peripheral edema.
- clinically relevant electrolyte disturbances and acid-base imbalance.

In general, the risk of fluid/solute overload causing congested states and/or electrolyte disturbances is directly proportional to the volume of the products intravenously administered.

Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.

#### **Use in patients at risk for sodium retention, fluid overload and edema**

0.9% Sodium Chloride Injection, USP should be used with particular caution, if at all, in patients with or at risk for:

- Hyponatremia
- Hyperchloremia
- Metabolic acidosis
- Hypervolemia
- Conditions that may cause sodium retention, fluid overload and edema (central and peripheral), such as patients with:
  - primary hyperaldosteronism,
  - secondary hyperaldosteronism, associated with, for example:
    - hypertension,
    - congestive heart failure,
    - liver disease (including cirrhosis),
    - renal disease (including renal artery stenosis, nephrosclerosis) or
    - pre-eclampsia.
- Medications that may increase the risk of sodium and fluid retention, such as corticosteroids

## **Risk of Hyponatremia**

Monitoring of serum sodium is important for all fluids. 0.9% Sodium Chloride Injection, USP has an osmolarity of 308 mOsmol/L.

High volume infusion must be used under specific monitoring in patients with cardiac or pulmonary failure, and in patients with non-osmotic vasopressin release (including Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)), due to the risk of hospital-acquired hyponatremia.

Acute hyponatremia can lead to acute hyponatremic encephalopathy (brain edema) characterized by headache, nausea, seizures, lethargy and vomiting. Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury.

## **Use in Patients with Severe Renal Impairment**

0.9% Sodium Chloride Injection, USP should be administered with particular caution, if at all, to patients with severe renal impairment. In such patients administration of 0.9% Sodium Chloride Injection, USP may result in sodium retention.

## **Special Populations**

### *Pregnancy and Lactation*

There are no adequate data from the use of 0.9% Sodium Chloride Injection, USP in pregnant or lactating women. Healthcare Practitioners should carefully consider the potential risks and benefits for each specific patient before administering 0.9 % Sodium Chloride Injection, USP.

### *Pediatrics*

Safety and effectiveness of 0.9% Sodium Chloride Injection, USP in pediatric patients have not been established by adequate and well controlled trials, however, the use of sodium chloride solutions in the pediatric population is referenced in the medical literature. The warnings, precautions and adverse reactions identified in the label copy should be observed in the pediatric population.

Plasma electrolyte concentrations should be closely monitored in the pediatric population because of their impaired ability to regulate fluids and electrolytes.

### *Geriatrics*

Clinical studies of 0.9% Sodium Chloride Injection, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from

younger subjects. Other reported clinical experience has not identified differences in the responses between elderly and younger patients.

When selecting the type of infusion solution and the volume/rate of infusion for a geriatric patient, one should consider that geriatric patients are generally more likely to have cardiac, renal, hepatic, and other diseases or concomitant drug therapy.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

### **Monitoring and Laboratory Tests**

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.

### **Adverse Reactions**

Adverse reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid and administration set for examination if deemed necessary.

### **Post-marketing Adverse Reactions**

The following adverse reactions have been reported in the post-marketing experience, listed by MedDRA System Organ Class (SOC), then, where feasible, by Preferred Term in order of severity.

#### **IMMUNE SYSTEM DISORDERS:**

Hypersensitivity/infusion reactions, including Hypotension, Pyrexia, Tremor, Chills, Urticaria, Rash, Pruritus

## GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS:

Infusion site reactions, such as Infusion site erythema, Injection site streaking, Burning sensation, Infusion site urticaria.

The following adverse reactions have been reported with other similar products:

- Hyponatremia
- Hyperchloremic metabolic acidosis
- Hyponatremia, which may be symptomatic
- Hyponatremic encephalopathy

## **Drug Interactions**

Caution is advised when administering 0.9% Sodium Chloride Injection, USP to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids or corticotropin [See also **Warnings and Precautions - Use in patients at risk for sodium retention, fluid overload and edema.**]

Caution is advised in patients treated with lithium. Renal lithium clearance may be increased during administration of 0.9% Sodium Chloride Injection, USP, resulting in decreased lithium levels.

Caution is advised when administering 0.9% Sodium Chloride Injection, USP to patients treated with drugs leading to an increased vasopressin effect. The below listed drugs increase the vasopressin effect, leading to reduced renal electrolyte free water excretion and may increase the risk of hyponatremia following treatment with intravenous fluids. (See **Special Warnings and Precautions for Use and Adverse Reactions**).

**Drugs stimulating vasopressin release** such as chlorpropamide, clofibrate, carbamazepine, vincristine, selective serotonin reuptake inhibitors (SSRIs), 3,4-methylenedioxy-N-methamphetamine, ifosfamide, antipsychotics, opioids.

**Drugs potentiating vasopressin action** such as chlorpropamide, non steroidal anti-inflammatories (NSAIDS), cyclophosphamide.

**Vasopressin analogues** such as desmopressin, oxytocin, vasopressin, terlipressin.

Caution is advised when administering 0.9% Sodium Chloride Injection, USP to patients treated with drugs that may increase the risk of hyponatremia, such as diuretics and antiepileptics (e.g., oxcarbazepine).

Studies have not been conducted to evaluate additional drug/drug or drug/food interactions with 0.9% Sodium Chloride Injection, USP.

## **Dosage and Administration**

As directed by a physician, dosage, rate, and duration of administration are to be individualized and depend upon the indication for use, the patient's age, weight, clinical condition, and concomitant treatment, and on the patient's clinical and laboratory response to treatment.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

Do not administer unless the solution is clear and the seal is intact.

0.9% Sodium Chloride Injection, USP in clear glass vials are intended for intravenous administration using sterile equipment. It is recommended that intravenous administration apparatus be replaced at least once every 24 hours.

Additives may be incompatible with 0.9% Sodium Chloride Injection, USP. Compatibility of additives with 0.9% Sodium Chloride Injection, USP must be assessed before addition. Additives known, determined or suspected to be incompatible should not be used.

Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH range of 0.9 % Sodium Chloride Injection, USP (~~0.9%~~) is appropriate.

The instructions for use of the medication to be added and other relevant literature must be consulted.

When introducing additives to 0.9% Sodium Chloride Injection, USP, aseptic technique must be used.

After addition, check for a possible color change and/or the appearance of precipitates, insoluble complexes or crystals.

Mix the solution thoroughly when additives have been introduced. Do not store solutions containing additives.

When other electrolytes or medicines are added to this solution, the dosage and the infusion rate will also be dictated by the dose regimen of the additions.

For single use only.

Discard any unused portion.



## **Overdosage**

An excessive volume of 0.9% Sodium Chloride Injection, USP may lead to hypernatremia (which can lead to CNS manifestations, including seizures, coma, cerebral edema and death) and sodium overload (which can lead to central and/or peripheral edema).

When assessing an overdose, any additives in the solution must also be considered.

Should overdose occur, prompt and careful clinical and laboratory assessment is essential. Effective therapeutic intervention based on the condition of the patient should be planned and executed as soon as possible.

The effects of an overdose may require immediate medical attention and treatment.

## **Storage**

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Store at 15°C to 30°C. Do not freeze.

## **Special Handling Instructions**

For single use only.

Discard any unused portion.

## **Dosage Form, Composition and Packaging**

0.9% Sodium Chloride Injection, USP is available in clear glass single-dose vials of 10 mL, 30 mL and 50 mL in boxes of 10.

Table 1 in the Summary Product Information section shows the volume, composition, ionic concentration, osmolarity and pH range of 0.9% Sodium Chloride Injection, USP.

Per mL: *Medicinal ingredient:* Sodium Chloride 9 mg. *Non-medicinal ingredients:* Hydrochloric Acid and Sodium Hydroxide (for pH adjustment); Water for Injection (Q.S.).

## **References**

1. 0.9% Sodium Chloride Injection, USP in Aviva Plastic Container (Baxter Corporation). Control no. 224943. Date of Revision: April 2, 2019.

**Prepared by:**

Juno Pharmaceuticals Corp.  
Mississauga, Ontario  
L5N 2X7

**Date of preparation:**

June 14, 2023